

IN THE U.S. PATENT AND TRADEMARK OFFICE

LARGE ENTITY TRANSMITTAL FORM

September 24, 2001

Transmitted herewith is an amendment in the above-identified application.

- The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	34	-	34	=	0	\$18	\$0.00
INDEPENDENT	4	-	4	=	0	\$80	\$0.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$270	\$0.00
						TOTAL	\$0.00

- ☐ Petition for () month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ A check in the amount of \$0.00 is enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Raymond C. Stewart, #21,066

RCS/KLR/BCF
0032-0261P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 295-8000

ATTACHMENTS: Paper and Disk copy of Substitute Sequence
Listing, Copy of the Notice to Comply

BOX SEQUENCE

PATENT

0042-0261P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: MORIBE, Toyoki et al. Conf.: 3176
Appl. No.: 09/856,662 Group: UNASSIGNED
Filed: May 24, 2001 Examiner: UNASSIGNED
For: METHOD FOR TYPING OF HLA CLASS I ALLELES

AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

September 24, 2001

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed July 24, 2001, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

In the Specification:

Please delete the Sequence Listing of Record. Please insert the Substitute Sequence Listing enclosed herewith immediately after the abstract.